SOSV is a global venture capital firm founded in 1995 and headquartered in New Jersey. The firm focuses on seed-to-growth investments in deep tech sectors, including biotech and life sciences, hardware and robotics, and cross-border software with emphasis on markets in Asia. It supports startups from early stages with investment capital as well as resources such as laboratories, collaborative spaces, and expert mentorship to accelerate product development and market traction. SOSV operates purpose-built programs to help portfolio companies raise follow-on funding, scale operations, and reach customers, often through structured matchmaking and access to a global network of investors. With a broad portfolio spanning hundreds of companies worldwide, SOSV aims to foster innovation, build vibrant entrepreneurial ecosystems, and contribute to sustainable technological advancement.

RA Capital Management is a Boston-based investment firm that provides multi-stage capital to public and private healthcare, life sciences, and planetary health companies. The firm supports management teams from early seed rounds to later financings, seeking to drive value through scientific and clinical data, product development, and commercialization. It complements capital with value-added services such as board representation, executive recruitment, and market intelligence through its TechAtlas research platform. The company also operates Raven, a healthcare incubator that helps entrepreneurs build biomedical ventures, and emphasizes a collaborative, data-driven approach and long-term relationships. RA Capital pursues social responsibility by advocating for affordable medicines and industry advancement, and it invests across U.S. and European opportunities, including early-stage and growth-stage rounds.

OrbiMed is a global healthcare investment firm based in New York that funds companies across the healthcare spectrum. It uses multiple strategies, including private equity for startups and growth-stage companies, private credit and royalty financing for intellectual property and medical diagnostics, and public equity investments. The firm targets biopharmaceuticals, biotechnology, medical devices, diagnostics, digital health, and health IT, supporting development of new therapies and health technologies. OrbiMed operates internationally with offices in major markets and manages substantial assets across public and private investments, staffed by a team of professionals to identify opportunities and support portfolio companies.

Eli Lilly and Company is a global biopharmaceutical company engaged in discovering, developing, manufacturing, and marketing medicines across neuroscience, cardiometabolic, cancer, and immunology. The company operates manufacturing and distribution facilities in the United States, Puerto Rico, and multiple countries, with products sold in about 135 markets worldwide. Through ongoing research and development, Lilly aims to deliver therapies that improve patient outcomes and access to medicines. Its portfolio includes treatments such as Mounjaro and Jardiance for cardiometabolic diseases, Verzenio and Jaypirca for cancer, Trulicity and Humalog for diabetes, and Taltz and Olumiant for immunology, among others. Lilly emphasizes safety and quality in manufacturing and supports patients through educational and support initiatives, reflecting a long history of pharmaceutical leadership and a commitment to advancing personalized medicine.

Novo Nordisk is a global healthcare company focused on discovering, developing, and delivering medicines for serious chronic diseases, with a core emphasis on diabetes care. The organization produces and distributes insulin and other therapies aimed at treating diabetes and related conditions, while investing heavily in scientific research and biopharmaceutical innovation. Through partnerships and sustained commitments to accessibility, Novo Nordisk seeks to improve patient outcomes and support health systems worldwide. The company operates across many markets, supported by its production of insulin pens and a broad portfolio addressing obesity, rare blood and endocrine disorders, and other chronic diseases. It pursues long-term social responsibility and sustainability as integral to its business model.

Qiming Venture Partners is a China-based venture capital firm founded in 2006, with offices in Shanghai, Beijing, Suzhou, Hong Kong and Singapore. It backs early and growth-stage technology, consumer and healthcare companies, applying deep industry knowledge and hands-on support to help portfolio companies scale. The firm manages US-dollar and RMB funds and maintains a global footprint, including a dedicated US arm, Qiming Venture Partners USA, to pursue cross-border opportunities in healthcare, therapeutics and digital health. Since inception, it has invested in more than 530 companies and achieved more than 200 exits via IPOs, M&A or other means, with over 70 portfolio companies reaching unicorn or super unicorn status. Qiming emphasizes long-term partnerships with entrepreneurs, aligning resources and networks to drive innovation and societal progress across its portfolio.

Alexandria Venture Investments is the strategic venture capital arm of Alexandria Real Estate Equities. It provides seed through growth capital to life science and technology companies developing breakthrough therapies, diagnostics, research tools, agrifoodtech, agtech, digital health, and related platforms. Backed by the parent company’s industry experience and scientific advisory network, the firm leverages long-standing relationships and domain expertise to support early to growth-stage ventures aiming to translate scientific advances into practical healthcare and technology solutions.

ARCH Venture Partners is a Chicago-based venture capital firm founded in 1986 that concentrates on science-driven startups, especially in life sciences, biotechnology, healthcare, and related technologies. It backs companies co-founded by scientists and entrepreneurs and supports commercialization of innovations developed at academic research institutions and national laboratories. The firm takes a long-term, hands-on approach, leveraging its network to assist portfolio companies from inception to market realization and to build transformative enterprises. ARCH has raised ten venture funds totaling over $3 billion and has invested in more than 150 companies worldwide, reflecting a focus on strategic value creation and governance.

Founded in 1985, The Invus Group is a global private equity firm that partners with entrepreneurs, founders and management teams across the company lifecycle. Blending a family-office approach with multi-strategy investing, it supports transformative growth in sectors including consumer products and services, technology, life sciences, software, agtech, industrials, education and medical devices. The firm pursues long-term value creation through strategic insight, capital and execution, investing in companies from early stages to mature businesses and providing both lead investments and co-investments in private transactions worldwide. It maintains a global footprint with offices in New York, London, Paris and Hong Kong and has a flexible structure designed to align incentives with partners over time.

Founded in 2020, the European Innovation Council is a Brussels-based venture capital initiative that supports top innovators, entrepreneurs, small companies, and researchers with bright ideas. It co-invests with private investors in early-stage startups, prioritizes deep technology ventures, and pursues ESG-positive impacts to accelerate commercialization and scale-up.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focusing on life sciences. It finances start-ups, early-stage companies, corporate spin-offs, and occasional turnarounds in biopharmaceuticals, biotech, medical devices, and related areas. The firm often acts as a lead or cornerstone investor and is frequently the first institutional backer in Series A rounds, maintaining an active role including board seats from formation through exit. It pursues global opportunities and emphasizes thorough due diligence on portfolio companies, including management and intellectual property considerations. The firm was established in 1972.

Vivo Capital is a global healthcare investment firm founded in 1996 and based in Palo Alto, California, with offices in Asia. It operates a multi-fund platform spanning growth equity, private equity including buyouts, venture capital, and public equity, and invests broadly in biotechnology, pharmaceuticals, medical devices, and healthcare services across major markets. The firm pursues opportunities worldwide, supporting companies at various development stages with a team of physicians, scientists, entrepreneurs, operating executives, and industry experts who contribute deep sector insight. It manages approximately $5.8 billion in assets under management.

Samsara BioCapital is a Palo Alto, California-based biotechnology investment firm founded in 2016 that focuses on supporting transformative therapeutics. The firm seeks opportunities in the healthcare sector across the United States and invests in biotechnology companies with the potential to advance patient care. With a team drawn from scientific, medical, and business backgrounds, Samsara BioCapital aims to accelerate the development and commercialization of innovative drugs through strategic partnerships and hands-on collaboration. The approach emphasizes rigorous scientific evaluation and value creation for portfolio companies, helping entrepreneurs turn ideas into therapies with meaningful patient impact.

Pfizer is a leading global pharmaceutical company that develops, manufactures, and markets medicines and vaccines across a broad range of therapeutic areas. It maintains an extensive portfolio focused on wellness, prevention, and treatment and pursues an industry-leading pipeline of promising medicines with potential to address diseases such as Alzheimer's and cancer. The company sells prescription drugs and vaccines worldwide, with international sales representing about 40% of revenue and emerging markets contributing significantly. Top products include Prevnar 13, Eliquis, and Vyndaqel. Pfizer conducts research and development, manufacturing, and global commercialization at scale, supported by a large manufacturing footprint and workforce.

Redmile Group is a San Francisco-based investment firm focused on healthcare, including life sciences and oncology; it engages in venture, growth and crossover investing and operates an office in New York.

Venrock is a Palo Alto-based venture capital firm with a history dating to 1969 as the venture capital arm of the Rockefeller family. It concentrates on technology and healthcare, providing seed and early-stage funding to entrepreneurs pursuing disruptive ideas. Its portfolio has included Apple, Intel, Illumina, Gilead Sciences, Nest, DoubleClick, Endeca, SlideShare, Athenahealth, and Tudou, among others, illustrating its experience across software, hardware, life sciences, and digital health. Venrock operates with a global perspective and maintains offices in Palo Alto, California and New York City, supporting startups through long-term partnerships and active involvement in company building.

Forbion is a global venture capital firm based in Naarden, Netherlands, focused on biotech innovations and sustainable solutions to improve human and planetary health. It invests across human health, planetary health and the bioeconomy, spanning pre-clinical, early clinical and growth stages, and combines company building with venture capital while integrating ESG principles. With two decades of experience and about €5 billion under management across 11 funds, Forbion backs companies in Europe and North America across life sciences, pharmaceuticals and biotechnology sectors.

Morningside Group is a venture capital firm founded in 1986, originally established as a family office for the Chan family, and is based in the greater Boston area. The firm makes venture investments in companies with novel science and technology, pursuing a long-term, patient approach to company-building and emphasizing ethical practices. Its investment focus spans life sciences, digital health, artificial intelligence, materials science, and information technology. In addition to its investment activities, Morningside supports charitable initiatives in education, research, and healthcare, with partnerships including the Harvard T.H. Chan School of Public Health, UMass Chan Medical School, and the MIT Morningside Academy for Design.

Mission BioCapital is a life sciences venture capital firm established in 2009 and based in Cambridge, Massachusetts, that funds early-stage biotechnology companies and supports them through clinical development. The firm emphasizes mentorship and practical assistance, offering entrepreneurs access to laboratory space, incubator networks, and programs designed to accelerate progress and secure follow-on funding. Its approach combines capital with hands-on guidance across discovery, development, and commercialization, leveraging a history of supporting dozens of startups. Through a broad ecosystem in the United States and Europe, Mission BioCapital aims to translate scientific discoveries into tangible solutions by pairing funding with operational support, expert advice in areas such as drug discovery, legal, and accounting, and strategic mentorship to help portfolio companies reach milestones and attract subsequent investment.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco, with offices in Canada, the United States, and Europe. The firm invests across the healthcare sector at all stages, with emphasis on the discovery and development of novel therapeutics, including pharmaceuticals, biotechnology, medical devices, and life sciences. Versant combines investment, operating, and scientific expertise to support portfolio companies through strategic guidance and hands-on involvement in company building. The firm manages substantial capital, enabling a hands-on approach to helping entrepreneurs build durable companies addressing high unmet medical needs.

Deep Track Capital is a Greenwich, Connecticut-based venture capital investment firm that concentrates on life sciences and biotechnology. It partners with management teams of innovative public and pre-IPO biotech companies, offering capital, strategic guidance, and access to its industry network. The firm aims to lead transactions, build large syndicates, and participate in rounds led by other investors, leveraging expertise in healthcare finance, biotech investing, and drug development to support portfolio companies through development and growth.

Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. It provides venture assistance, strategic advice, and capital to technology-driven entrepreneurs across a broad range of sectors including artificial intelligence, digital health, sustainability, consumer and enterprise technology, and medical technologies, supporting startups from early to late stages. The firm emphasizes innovative business models and science- and design-driven approaches to building long-lasting companies, often working closely with portfolio founders to scale products, markets, and operations. Based in Menlo Park, California, Khosla Ventures pursues opportunities that address meaningful global challenges and aims to help entrepreneurs create durable businesses that deliver impact and growth.

Deerfield Management is a New York-based healthcare investment firm established in 1994. It manages investments across public and private markets in healthcare products and services, including therapeutics, medical devices, diagnostics, digital health, and health services. The firm combines capital deployment with research and strategic intelligence through Deerfield Intelligence and supports innovation via Deerfield Discovery and Development (3DC) and a philanthropic foundation focused on education, healthcare access, and health outcomes.

Casdin Capital is an investment firm focused on life sciences and healthcare. Founded in 2012 by Eli Casdin and based in New York, it seeks opportunities across the life sciences spectrum, including biotechnology, digital health, oncology, agtech, and healthcare services. The firm pursues early- to late-stage private investments and, at times, long-short equity strategies, leveraging data-driven insights, molecular information, and precision medicine to identify transformative opportunities. It emphasizes patient capital, disciplined investing, and strong collaborations to support companies advancing diagnostics, therapeutics, and sustainable solutions. By capturing and processing data to unlock breakthroughs, Casdin Capital backs teams with the potential to transform modern medicine.

Logos Capital is a biotechnology-focused investment firm headquartered in San Francisco. The company applies disciplined, data-driven diligence across medical, scientific, and clinical disciplines to identify transformative therapies in healthcare. By combining in-house analytics with rigorous clinical evaluation, Logos Capital seeks to back life-changing therapeutics with strong value propositions. The firm emphasizes rigorous opportunity identification, thorough clinical trial underwriting, and proactive risk management, leveraging advanced analytics to predict trial outcomes and support informed investment decisions. Its approach aims to deliver compelling returns while contributing to patient outcomes by supporting companies with transformative technologies.

Atlas Venture is a Cambridge-based venture capital firm with a 30-year history of building life sciences companies. Founded in 1980, it focuses on early-stage opportunities in biotechnology, biopharmaceuticals, diagnostics, medical devices, and related life sciences, as well as technology sectors. The firm uses a seed-led venture creation approach and often leads initial rounds, providing strategic guidance and board representation to portfolio companies. Its portfolio has included the development of more than 25 medicines and the launch of eight startups through its incubator program, and it has facilitated 43 IPOs and 39 M&A exits. Atlas operates with a global reach across the United States and Europe, supporting life science entrepreneurs in translating scientific advances into therapies and commercial opportunities.

New Enterprise Associates is a leading venture capital firm founded in 1977 and based in Menlo Park, California. It backs entrepreneurs across stages and a broad range of sectors, with a focus on technology and healthcare. The firm provides capital and operational support, along with domain expertise, strategic counsel, and resources to help founders address technical challenges, advance product development, and pursue market expansion. NEA emphasizes long-term partnerships, offering guidance through changing market conditions and helping portfolio companies reach milestones from seed stages to IPOs. It invests globally, including the United States, Asia, and other regions, and targets software, consumer technology, information technology, healthcare technology, life sciences, energy technology, and related industries. With a track record of portfolio company IPOs and acquisitions, NEA has accumulated substantial committed capital and a worldwide footprint to support transformative innovations.

U.S. Venture Partners is a Menlo Park, California-based venture capital firm that backs early-stage technology and healthcare companies. With more than thirty years of operation, it helps entrepreneurs transform ideas into growth companies, focusing on enterprise software, IT security, consumer internet, mobile, e-commerce, and IT-enabled healthcare services. The firm targets startups in information technology and healthcare that can scale in the United States, and in some cases Israel, and it emphasizes collaboration with teams that include former entrepreneurs, technologists, executives, and industry experts. USVP invests in software, healthcare, cybersecurity, and related technology-enabled sectors, supporting portfolio companies through early development and scale-up.

Illumina is a technology company that develops and sells instruments, reagents, and services for genetic analysis in life science and clinical laboratories. Its high-throughput sequencing platforms enable whole-genome sequencing in humans and other organisms, while lower-throughput systems support targeted applications such as viral and cancer screening. The company also markets microarrays for lower-cost, focused genetic screening with consumer and agricultural applications. Illumina generates over 90% of its revenue from sequencing instruments, consumables, and services, and its products and services support disease research, drug development, and the creation of molecular tests for clinical use, contributing to genomics-enabled personalized medicine.

Merck is a German science and technology company based in Darmstadt. Founded in 1668, it operates three main business areas: Life Science, which provides laboratory consumables and instruments for researchers; Electronics, which offers specialty materials for manufacturing semiconductors and displays; and Healthcare, which develops and sells branded pharmaceuticals with significant concentrations in oncology, neurology and fertility, supported by patient devices and digital health solutions. The company serves customers worldwide across Europe, Africa, Asia, Oceania and Latin America. Historically, the business is distinct from Merck & Co. in the United States and Canada, which operates under a different name in those markets. Merck is one of the oldest operating chemical and pharmaceutical companies.

Omega Funds is a Boston-based venture capital firm founded in 2004 that focuses on early-stage investments in healthcare and biotech. It backs companies across biotechnology, pharmaceuticals, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software-as-a-service, with activity in North America and Western Europe. The firm manages multiple funds and operates as a registered investment adviser, leveraging its network to support entrepreneurs and advance innovations in medicine and related technologies.

TCG Crossover is a science-driven venture capital firm focused on healthcare and biotechnology. It invests in biotechnology and pharmaceutical companies across the United States and Europe, supporting the development of medicines through a network of scientific advisors and resources that help navigate clinical and regulatory challenges. The firm has teams in Palo Alto and New York City and pursues long-term partnerships with entrepreneurs to translate cutting-edge science into meaningful patient outcomes.

F-Prime Capital is a venture capital firm based in Cambridge, Massachusetts, with a global portfolio of over 400 companies focused on healthcare and technology. It backs therapeutics, medtech, and healthtech and services as well as enterprise software, fintech, frontier tech and crypto, investing across the Americas, Europe and Asia and across stages from early to later as opportunities arise. The firm relies on a multidisciplinary team of scientists, engineers, physicians, operators and investors to help portfolio companies accelerate scalable growth and translate bold ideas into breakthroughs. With more than 50 years in operation and about $4.8 billion under management, F-Prime Capital provides strategic guidance and deep domain expertise to support ambitious teams worldwide.

Founded in 2000, Flagship Pioneering is a Cambridge, Massachusetts-based venture capital firm that conceives, creates, resources, and grows first-in-category companies in health technology, biotechnology, life sciences, and related fields. It accelerates advances in biology, engineering, medicine, energy, and beyond by combining scientific innovation with entrepreneurial leadership and professional capital management to bring seemingly unreasonable propositions through an evolutionary, company-building process. The firm focuses on developing and supporting early-stage ventures that aim to transform human health and sustainability.

The Column Group is a San Francisco-based venture capital firm that invests in biotechnology and life sciences companies, with a focus on drug discovery, oncology, and technology-enabled healthcare. The firm supports companies from early discovery through later-stage development, pursuing a long-term, platform-based approach designed to generate multiple product opportunities rather than a single exit. It backs startups addressing cancer, inflammation, infectious disease, metabolic, cardiovascular, and nervous system disorders, typically allocating between $15 million and $30 million per deal. The Column Group manages over $4 billion in assets and operates as an investment adviser, leveraging a nationwide US focus for opportunities in healthcare and related sectors.

SR One is the corporate venture capital arm of GlaxoSmithKline. It invests globally in emerging life science companies pursuing innovative science with potential to significantly improve medical care. The firm adopts a back-and-build approach, supporting founders and entrepreneurs to translate scientific discoveries into new medicines. With a transatlantic presence on the West Coast of the United States and London, SR One provides geographic reach, expertise, and timely business support to its portfolio. Since 1985, SR One has invested about 800 million across more than 180 companies.

Northpond Ventures is a science-driven venture capital firm specializing in growth capital, headquartered in Bethesda, Maryland, with offices in San Francisco, California, and Cambridge, Massachusetts. Founded in 2018, it focuses on life sciences and technology sectors, including diagnostics, digital health, health tech, therapeutics, and artificial intelligence and machine learning. The firm backs growth-stage companies advancing biomedical research and technology-enabled healthcare, aiming to translate scientific advances into commercial solutions.

Alumni Ventures is a venture capital firm founded in 2014 and based in Manchester, New Hampshire. It connects accredited individual investors with startup deals and co-invests alongside established venture capital firms across multiple stages, from seed to growth. The firm provides access to diversified portfolios through funds, syndicates, and investing clubs, supported by a large network of community members and individual investors. It invests across sectors and geographies, with a focus on transparency and due diligence in collaborative investments with leading firms such as Andreessen Horowitz, Sequoia, and Y Combinator. Alumni Ventures operates internationally with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo and has raised substantial capital to back founders with strategic capital and resources.

HBM Healthcare Investments is a Swiss investment firm founded in 2001 that focuses on delivering access to a globally diversified portfolio of healthcare companies. Headquartered in Switzerland, the firm targets opportunities across human medicine, biotechnology, medical technology and diagnostics, investing in both private and public companies with established or near-market products. It emphasizes active portfolio management and provides strategic guidance to portfolio companies to support value creation. By leveraging demographic trends and medical innovation, the firm seeks attractive returns while maintaining a diversified asset mix that includes private holdings, public equities and funds. The company is noted for an attractive dividend policy with a yield around five percent.

EcoR1 Capital is a San Francisco-based investment firm focused on the biotechnology sector. Founded in 2012, the company operates as an investment adviser and venture investor, seeking to identify and support innovative therapeutic solutions with the potential to improve patient outcomes. It provides investment services to pooled vehicles and participates in biotech investments across private and public markets, reflecting a commitment to advancing medical research.

Sofinnova Investments is a venture capital firm founded in 1976 and headquartered in Menlo Park, California, with offices in La Jolla, Montreal and Tokyo. It backs life sciences and information technology companies across the United States and Europe, from seed through early and growth stages. In life sciences, it targets clinical-stage pharmaceutical and biotechnology companies, drug discovery platforms, and medical technology addressing diseases with unmet medical needs, including oncology, respiratory, dermatology, ophthalmology, neurology and women's health. In information technology, it supports product-oriented software, enterprise IT solutions and telecommunications infrastructure. The firm often requires board participation for early-stage lead or co-lead investments and emphasizes hands-on guidance to help entrepreneurs build global businesses.

Boxer Capital is a biotechnology investment firm that invests in private and public companies across the full drug development lifecycle, from early discovery to late-stage clinical and commercial programs. Based in the United States, it operates as part of the Tavistock Group and concentrates on biotechnology, life sciences, and precision and specialized medicine. The firm emphasizes disciplined, science-driven analysis and a multidisciplinary approach, with bottom-up idea generation supported by experienced scientists, aiming to advance innovative targets and therapies that improve patient care. It pursues opportunistic venture investments across private and public markets.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

Nextech Invest is a Zurich-based investment firm dedicated to early-stage healthcare and life sciences companies, with a particular focus on oncology and precision medicine. It identifies and invests in emerging biotechnology ventures, providing support through scientific validation and value creation across the company’s lifecycle. The firm pursues opportunities globally, funding companies across continents and enabling technologies that advance therapies, diagnostics, and medical technologies. It operates independently in the life sciences and related fields and aims to build a portfolio of promising ventures with potential to improve cancer care and related healthcare outcomes.

Kurma Partners is a Paris-based European investment firm that funds innovation in healthcare and biotechnology. It invests across development stages, from early research to growth, with a focus on therapeutics, diagnostics, and HealthTech/MedTech. The firm works with leading research centers and hospitals, maintains a broad European footprint with a strong presence in France, and pursues responsible investing aligned with ESG principles. Its portfolio emphasizes sustainable impact and collaboration with researchers and entrepreneurs to advance medical solutions.

5AM Ventures is a San Francisco-based venture capital firm that provides seed- and early-stage funding to companies in the life sciences, healthcare, and related technology sectors. Its portfolio focuses on biopharmaceuticals, medical technology, and life science instruments, with investments across the United States. Founded in 2002 by John Diekman and Andrew Schwab, the firm operates from its San Francisco base and maintains an office in Boston. 5AM Ventures partners with scientists and entrepreneurs to advance breakthrough therapies and diagnostic tools, supporting companies through early development and growth.

Takeda is a global biopharmaceutical company focused on developing and delivering medicines across oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. It researches, develops, manufactures, markets, and sells pharmaceutical drugs and vaccines to improve patient health worldwide. The company maintains a diversified geographic footprint, with substantial activity in the United States, Japan, Europe and Canada, and operates a broad portfolio of therapies designed to address unmet medical needs. Takeda emphasizes research and development, pursuing innovation in gastrointestinal and inflammatory diseases, oncology, and neuroscience, while upholding commitments to patient outcomes, ethical practices, and sustainability. It is Japan’s largest pharmaceutical company by several metrics.

Seventure Partners is a Paris-based venture capital firm established in 1997 that backs early-stage to growth companies across Europe and beyond. The firm focuses on two main domains: Life Sciences and Technology/Digital, investing in areas such as biotech, healthcare, nutrition, B2B software, fintech, cybersecurity, and related sectors, with an emphasis on building European leaders. It operates with offices in Paris and other major European cities and maintains an international reach including North America, Europe, Asia-Pacific, and the Middle East and Africa. Seventure partners with entrepreneurs by providing capital, strategic guidance, and access to its network to support growth and innovation, aiming to foster scientific and technological progress while contributing to economic development.

IP Group is a global science and technology investment company that identifies, backs, and grows university spin-outs and IP-based businesses. Through strategic partnerships with universities and research institutions, it provides capital, expertise, and commercialization support to accelerate the development of innovations in healthtech, deeptech, and clean tech. The firm focuses on early-stage ventures, seeks to create value for shareholders and partners, and aims to generate financial returns alongside positive social and environmental impact in line with sustainable development goals. IP Group leverages its network, governance discipline, and portfolio-building capabilities to scale portfolio companies worldwide.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.